Felipe Perez

Dr. Felipe Perez

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2022 in Journal of Biomedical Science
Verified
Journal Article
Open access
PDF file
FPFelipe Perez
Felipe Perez
JBJoseph P. Bandeira
Joseph P. Bandeira
CCCristina N. Perez Chumbiauca
Cristina N. Perez Chumbiauca
DLDebomoy K. Lahiri
Debomoy K. Lahiri
JMJorge Morisaki
Jorge Morisaki
MRMaher Rizkalla
Maher Rizkalla
We provide a multidimensional sequence of events that describe the electromagnetic field (EMF) stimulation and biological system interaction. We describe this process from the quantum to the molecular, cellular, and organismal levels. We hypothesized that the sequence of events of these interactions starts with the oscillatory effect of the repeated electromagnetic stimulation (REMFS). These oscillations affect the interfacial water of an RNA causing changes at the quantum and molecular levels that release protons by quantum tunneling. Then protonation of RNA produces conformational changes that allow it to bind and activate Heat Shock Transcription Factor 1 (HSF1). Activated HSF1 binds to the DNA expressing chaperones that help regulate autophagy and degradation of abnormal proteins. This action helps to prevent and treat diseases such as Alzheimer’s and Parkinson’s disease (PD) by increasing clearance of pathologic proteins. This framework is based on multiple mathematical models, computer simulations, biophysical experiments, and cellular and animal studies. Results of the literature review and our research point towards the capacity of REMFS to manipulate various networks altered in aging, including delay of cellular senescence and reduction in levels of amyloid-β peptides. Results of these experiments using REMFS at low frequencies can be applied to the treatment of patients with age-related diseases. The use of EMF as a non-invasive therapeutic modality for Alzheimer’s disease, specifically, holds promise. It is also necessary to consider the complicated and interconnected genetic and epigenetic effects of the REMFS-biological system’s interaction while avoiding any possible adverse effects.

25 February 2025 in Exploration of Neuroscience
Verified
Journal Article
Open access
PDF file
FPFelipe Perez
Felipe Perez
BWBrett Walker
Brett Walker
JMJorge Morisaki
Jorge Morisaki
HKHaitham Kanakri
Haitham Kanakri
MRMaher Rizkalla
Maher Rizkalla
The use of neurostimulation devices for the treatment of Alzheimer’s disease (AD) is a growing field. In this review, we examine the mechanism of action and therapeutic indications of these neurostimulation devices in the AD process. Rapid advancements in neurostimulation technologies are providing non-pharmacological relief to patients affected by AD pathology. Neurostimulation therapies include electrical stimulation that targets the circuitry-level connection in important brain areas such as the hippocampus to induce therapeutic neuromodulation of dysfunctional neural circuitry and electromagnetic field (EMF) stimulation that targets anti-amyloid molecular pathways to promote the degradation of beta-amyloid (Aβ). These devices target specific or diffuse cortical and subcortical brain areas to modulate neuronal activity at the electrophysiological or molecular pathway level, providing therapeutic effects for AD. This review attempts to determine the most effective and safe neurostimulation device for AD and provides an overview of potential and current clinical indications. Several EMF devices have shown a beneficial or harmful effect in cell cultures and animal models but not in AD human studies. These contradictory results may be related to the stimulation parameters of these devices, such as frequency, penetration depth, power deposition measured by specific absorption rate, time of exposure, type of cell, and tissue dielectric properties. Based on this, determining the optimal stimulation parameters for EMF devices in AD and understanding their mechanism of action is essential to promote their clinical application, our review suggests that repeated EMF stimulation (REMFS) is the most appropriate device for human AD treatments. Before its clinical application, it is necessary to consider the complicated and interconnected genetic and epigenetic effects of REMFS-biological system interaction. This will move forward the urgently needed therapy of EMF in human AD.

10 April 2025 in IEEE Journal of Translational Engineering in Health and Medicine
Verified
Journal Article
Open access
FPFelipe Perez
Felipe Perez
JMJorge Morisaki
Jorge Morisaki
HKHaitham Kanakri
Haitham Kanakri
MRMaher Rizkalla
Maher Rizkalla
AAAhmed Abdalla
Ahmed Abdalla
Late Onset Alzheimer’s Disease (LOAD) is the most common cause of dementia, characterized by the deposition of plaques primarily of neurotoxic amyloid- $\beta $ ( $A\beta $ ) peptide and tau protein. Our objective is to develop a noninvasive therapy to decrease the toxic A $\beta $ levels, using repeated electromagnetic field stimulation (REMFS) in the brain of Alzheimer’s disease patients. We previously examined the effects of REMFS on $A\beta $ levels in primary human brain (PHB) cultures at different frequencies, powers, and specific absorption rates (SAR). PHB cultures at day in vitro (DIV7) treated with 64 MHz with a SAR of 0.6 W/Kg, one hour daily for 14 days (DIV 21) had significantly reduced (p =0.001) levels of secreted $A\beta $ -42 and $A\beta $ -40 peptide without evidence of toxicity. The EMF frequency and power, and SAR levels used in our work is utilized in MRI’s, thus suggesting REMFS can be further developed in clinical settings to lower ( $A\beta $ ) levels and improve the memory in AD patients. These findings and numerous studies in rodent AD models prompted us to design a portable RF device, appropriate for human use, that will deliver a homogeneous RF power deposition with a SAR value of 0.4-0.9 W/kg to all human brain memory areas, lower ( $A\beta $ ) levels, and potentially improve memory in human AD patients.The research took place at the Indiana University School of Medicine (IUSM) and Purdue University Indianapolis. The first phase was done in PHB cultures at the IUSM. Through this phase, we found that a 64 MHz frequency and an RF power deposition with a SAR of 0.4-0.6 W/kg reduced the (A $\beta $ ) levels potentially impacting Alzheimer’s disease. The second phase of the project was conducted at Purdue University, we used ANSYS HFSS (High Frequency Simulation System) to design the devices that produced an appropriate penetration depth, polarization, and power deposition with a SAR of 0.4-0.9 W/kg to all memory brain areas of several numerical models. In Phase II-B will validate the device in a physical phantom. Phase III will require the FDA approval and application in clinical trials.The research parameters were translated into a designed product that fits comfortably in human head and fed from an external RF source that generates an RF power deposition with a SAR of 0.4-0.9 W/kg to a realistic numerical brain. The engineering design is flexible by varying the leg capacitors of the Meander Line Antenna (MLA) devices. Thermal outcomes of the results guarantee less than 0.5 C temperature increase within one-hour time of exposure, which can be used in clinical trials for AD patients. Design parameters include dimension of the coil, the MLA structure, conducting material, and capacitance values with the produced EM fields. The flexible design was achieved by varying the additive capacitance between conductors, and via a hybrid approach integrating a birdcage with sixteen MLA. A coil antenna size within 16 cm radius and 13 cm length was achieved. A capacitance between 6.9 nF and 9.2 nF were observed when copper materials with 16 conductors were used to achieve the research parameters in focus.The medical project proposed here has three phases: The initial phase of determining the research parameters for reducing A $\beta $ levels in human brain cultures and animal studies was completed at the IUSM. The translational engineering design of the REMS device and the numerical head and Antenna devices was successfully completed and presented in this paper by Purdue University and IUSM. Future phases will require manufacture and experimental validation of the REMS device with FDA approval for human application. Clinical impact: Our biological studies in human brain cultures showed that an RF power with a SAR of 0.4-0.9 W/kg at 64 MHz, lowered A $\beta $ levels, which potentially will prevent the death of the brain neurons and improve memory in AD. The fact that we found a safe RF power deposition with a SAR value associated with the proposed biological effects in human neurons and that 64 MHz provides a penetration depth of 13.5 cm that reaches all memory areas in a human brain makes the design and manufacture of this device of high clinical impact in the study of these exposures on the treatment of Alzheimer’s and other protein associate diseases. Also, 64 MHz and RF power deposition with similar SAR levels are administer routinely in routine MRI for more than 4 decades makes it a safe framework for these novel therapeutic strategy.Clinical and Translational Impact Statement: The basic science work presented previously is both mechanistic and translational, and would advance the field of neuroscience as well as AD. This prompted us to joint efforts between the Indiana University School of Medicine and the electrical and computer engineering at Purdue University to design and develop a suitable EMF device for human treatments. Recently, our engineering team designed a birdcage antenna that generate a homogeneous RF power deposition with the same SAR values of our biological experiments in a realistic numerical human brain. Here, the engineering research has been extended to investigate the design of a portable flexible birdcage antenna that will enable adjustments to fit physical patient’s characteristics, such as geometry, head size, and tissue dimensions. This new device is expected to improve SAR uniformity and may reduce the likelihood of untreated regions in the brains of patients during treatments. Also, here we determined that the maximum temperature rise of these exposures was less than 0.5°C, which is a safe level per regulatory agencies. This study considers a portable device system that will achieve the research parameters and patient satisfaction regarding reliability and comfort.

15 January 2020
Verified
Book Chapter
Open access
PDF file
FPFelipe Perez
Felipe Perez
JRJames Mina Rizkalla
James Mina Rizkalla
MJMatthew Jeffers
Matthew Jeffers
PSPaul Salama
Paul Salama
CCCristina N. Perez Chumbiauca
Cristina N. Perez Chumbiauca
MRMaher Rizkalla
Maher Rizkalla
The effects of electromagnetic fields on living organs have been explored with the use of both biological experimentation and computer simulations. In this paper we will examine the effects of the repeated electromagnetic field stimulation (REMFS) on cell cultures, mouse models, and computer simulations for diagnostic purposes. In our biological experiments we used 50 MHz and 64 MHz since this is approved in MRI systems. REMFS upregulated pathways that control the aging process such as proteostasis. REMFS delayed and reversed cellular senescence in mouse and human cell cultures. More recently we determined that REMFS decreases toxic protein beta amyloid levels, which is the cause of Alzheimer’s disease (AD), in human neuronal cultures. The mechanism of these effects is the reactivation of the heat shock factor 1 (HSF1). HSF1 activation is a quantum effect of the EMF-oscillations on the water that surrounds a long non-coding RNA, allowing it to then bind and activate the HSF1. We also performed electromagnetic (EM) computer simulations of virtual prototypes of bone cancer, femur fracture, and diabetic foot ulcers utilizing different frequencies and power applications to build an accurate differential diagnosis. These applications indicate the feasibility of subsequent practical models for diagnosing and treating human diseases.

9 September 2022 in Journal of Biomedical Science
Verified
Journal Article
Open access
PDF file
FPFelipe Perez
Felipe Perez
JBJoseph P. Bandeira
Joseph P. Bandeira
CCCristina N. Perez Chumbiauca
Cristina N. Perez Chumbiauca
DLDebomoy K. Lahiri
Debomoy K. Lahiri
JMJorge Morisaki
Jorge Morisaki
MRMaher Rizkalla
Maher Rizkalla

8 August 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
FPFelipe Perez
Felipe Perez
JBJoseph Paul Bandeira
Joseph Paul Bandeira
JMJorge Morisaki
Jorge Morisaki
HKHaitham Kanakri
Haitham Kanakri
MRMaher Rizkalla
Maher Rizkalla
Electromagnetic field stimulation (EMFS) has emerged as a promising modality for regulating the structural dynamics of biological macromolecules implicated in aging and neurodegenerative disorders. In particular, EMFS can alter the conformation of abnor-mally folded proteins, such as amyloid-β (Aβ) peptides and their aggregates, thereby mitigating pathological protein aggregation and delaying neurodegeneration. The molecular interactions at play are governed by quantum mechanical forces acting on interfacial water molecules adjacent to hydrophilic protein surfaces. These interactions modulate the structural and functional dynamics of key proteins implicated in aging and neurodegeneration, including Heat Shock Factor 1 (HSF1) and amyloid-beta (Aβ). This study advances the mechanistic understanding of water-mediated quantum effects, analogous to those observed in enzyme catalysis, highlighting the role of proton tunneling within extensive hydrogen-bond networks. These phenomena are especially prevalent in intrinsically disordered proteins (IDPs), which are central to proteostasis and highly susceptible to structural perturbations that lead to post-translational modifications associated with aging and neurodegeneration. We propose repeated electromagnetic field stimulation (REMFS) as a novel thera-peutic strategy to restore the native conformational states of critical IDPs, including Aβ, α-synuclein, and Tau. Furthermore, REMFS appears to reverse the age-related post-translational modifications of key proteostasis regulators, such as HSF1 and other heat shock proteins. Through quantum-mechanical modulation, REMFS influences multiple Alzheimer’s disease (AD) pathways, demonstrating the potential to prevent or reverse pathological changes in cellular and organismal models. These findings support the further development of REMFS as an anti-amyloid and anti-aggregation therapy for AD and related neurodegenerative conditions.